As the biology of the CCL17/CCL22-CCR4 chemokine–receptor axis is being further elucidated, interest in its constituent molecules as potential therapeutic targets for the treatment of allergies, autoimmune diseases, and cancer has been growing. Here, CCL22 is linked to allergic disease.